Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
1 hedge funds and large institutions have $4K invested in Sierra Oncology, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 108 closing their positions.
99% less funds holding
Funds holding: 109 → 1 (-108)
100% less funds holding in top 10
Funds holding in top 10: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $1.06B → $4K (-$1.06B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 108
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$183M |
| 2 |
VI
Versor Investments
New York
|
-$86.9M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$72.3M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$64.6M |
| 5 |
BlackRock
New York
|
-$64.3M |
SRRA Hedge Fund Activity: Q3 2022 in Review
1 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2022, worth a combined $4K — down 100% from $1.06B a quarter earlier.
Sellers outnumbered buyers: 108 funds closed out of SRRA and 0 opened new positions — a net loss of 108 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vivo Capital, exiting entirely with an estimated $183M sold.
- 1 institutional investor held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2022, down from 109 in Q2 2022.
- Funds reported $4K of Sierra Oncology, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2022 and 108 closed out, a net change of -108 holders.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2022 was Vivo Capital, an estimated $183M sold.
Based on aggregated 13F filings for Q3 2022.